Skip to main content
. 2021 Oct 1;28(6):925–932. doi: 10.1177/13524585211047223

Table 3.

Number of AQP4–IgG–seropositive participants receiving inebilizumab for ⩾4 years by infection grade and year.

Year after inebilizumab initiation Grade, n
1 2 3 4
1 29 14 2 0
2 19 13 3 0
3 19 11 1 0
4 15 9 2 0
⩾ 5 8 6 2 1

AQP4: aquaporin-4; Ig: immunoglobulin.